Cancer Res Treat.  2015 Jul;47(3):379-386. 10.4143/crt.2014.021.

A Survey of Stereotactic Body Radiotherapy in Korea

• Bae SH
• Kim MS
• Jang WI
• Kay CS
• Kim W
• Kim ES
• Kim JH
• Kim JH
• Yang KM
• Lee KC
• Chang AR
• Jo S

• KMID: 2148486
• DOI: http://doi.org/10.4143/crt.2014.021

Abstract

PURPOSE
The purpose of this study is to investigate the current status of stereotactic body radiotherapy (SBRT) in Korea. A nationwide survey was conducted by the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology (KROG 13-13).
MATERIALS AND METHODS
SBRT was defined as radiotherapy with delivery of a high dose of radiation to an extracranial lesion in < or = 4 fractions. A 16-questionnaire survey was sent by e-mail to the chief of radiation oncology at 85 institutions in June 2013.
RESULTS
All institutions (100%) responded to this survey. Of these, 38 institutions (45%) have used SBRT and 47 institutions (55%) have not used SBRT. Regarding the treatment site, the lung (92%) and liver (76%) were the two most common sites. The most common schedules were 60 Gy/4 fractions for non-small cell lung cancer, 48 Gy/4 fractions for lung metastases, 60 Gy/3 fractions for hepatocellular carcinoma, and 45 Gy/3 fractions or 40 Gy/4 fractions for liver metastases. Four-dimensional computed tomography (CT) was the most common method for planning CT (74%). During planning CT, the most common method of immobilization was the use of an alpha cradle/vacuum-lock (42%).
CONCLUSION
Based on this survey, conduct of further prospective studies will be needed in order to determine the appropriate prescribed doses and to standardize the practice of SBRT.

Keyword

Radiation oncology; Radiosurgery; Survey

MeSH Terms

Appointments and Schedules
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Electronic Mail
Four-Dimensional Computed Tomography
Immobilization
Korea
Liver
Lung
Neoplasm Metastasis
Radiation Oncology
Radiosurgery*
Radiotherapy

Figure

• 

  Fig. 1. (A) Cumulative adoption of stereotactic body radiotherapy (SBRT) after its introduction in 1997; green bar indicates institutions which have already been prepared to start SBRT in 2013. (B) The number of SBRT cases per year in each institution using SBRT as of June 2013.

• 

  Fig. 2. (A) Treatment sites applied stereotactic body radiotherapy (SBRT). (B) Cumulative adoption of SBRT for the two most common treatment sites (lung and liver).

• 

  Fig. 3. The prescribed doses for non-small cell lung cancer (A), lung metastases (B), hepatocellular carcinoma (C), and liver metastases (D) among institutions. SBRT, stereotactic body radiotherapy.

• 

  Fig. 4. Application rate of respiratory gating method to moving targets according to institution. SBRT, stereotactic body radiotherapy.

Reference

References

1. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951; 102:316–9.

2. Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K. Stereotactic body radiation therapy: scope of the literature. Ann Intern Med. 2011; 154:737–45.

3. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004; 60:1026–32.

4. Khrizman P, Small W Jr, Dawson L, Benson AB 3rd. The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings. Clin Colorectal Cancer. 2010; 9:136–43.

5. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009; 75:343–7.

6. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer. 2011; 117:4566–72.

7. Lock MI, Hoyer M, Bydder SA, Okunieff P, Hahn CA, Vichare A, et al. An international survey on liver metastases radiotherapy. Acta Oncol. 2012; 51:568–74.

8. Daly ME, Perks JR, Chen AM. Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol. 2013; 8:202–7.

9. Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013; 8:1050–8.

10. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101:1623–31.

11. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2011; 81:e305–16.

12. Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012; 7:1382–93.

13. Wigg AJ, Palumbo K, Wigg DR. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. J Gastroenterol Hepatol. 2010; 25:664–71.

14. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000; 18:2210–8.

15. Lausch A, Sinclair K, Lock M, Fisher B, Jensen N, Gaede S, et al. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. Br J Radiol. 2013; 86:20130147.

16. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010; 10:475.

17. Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010; 9:479–87.

18. Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012; 84:355–61.

19. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012; 118:5424–31.

20. Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 33:677–83.

21. Li W, Purdie TG, Taremi M, Fung S, Brade A, Cho BC, et al. Effect of immobilization and performance status on intrafraction motion for stereotactic lung radiotherapy: analysis of 133 patients. Int J Radiat Oncol Biol Phys. 2011; 81:1568–75.